Please note that this page is meant ONLY for Malaysian Doctors with a valid Medical Registration Number. Thank you.
Novel Therapeutic Approached for Prostate Cancer - Part 4
Presenters : Assoc. Prof. Dr. Marniza Saad & Prof. Dr. Ong Teng Aik
Posted in : Urology | Oncology | Novel Therapeutic Approached for Prostate Cancer
CPD Activity
Get 1 CPD credit & 15 reward points
About the Course
This is a 4th module of a 6-part course series on "Novel Therapeutic Approached for Prostate Cancer".
  • The series contains 6 modules and 6 sets of questions in total.
  • Doctors need to view all modules and attempt all 6 sets of questions to pass the series and earn 6 CPD credits in total.
  • Duration of this module: approximately 30 minutes.
  • Duration of total course series: 3 hours.
Module 4: Approaches to Castrate-Sensitive Prostate Cancer
Learning objectives:
  • Describe the rationale, role and options for androgen deprivation therapy in the management of patients with prostate cancer
  • Describe the best evidence-based management of castrate-sensitive prostate cancer
This CPD activity is done in collaboration with Johnson & Johnson Sdn Bhd.
Upon viewing the video and successfully completing the quiz in this module, you will be given 1 CPD point, that will be credited instantly in your MMA CPD account.
To pass this module, get at least 10 out 12 questions correct.

About the Presenters

Assoc. Prof. Dr. Marniza Saad
A/Prof Marniza Saad is a Clinical Oncologist at the Department of Clinical Oncology in Kuala Lumpur and an Associate Professor at Faculty of Medicine, University of Malaya (UM) Kuala Lumpur. After obtaining her Medical Degree from University of Wales College of Medicine, Cardiff in 1997, she underwent specialist training in Clinical Oncology at Velindre Cancer Centre, Cardiff UK and attained FRCR qualification in 2006. She was the Head of Department of Clinical Oncology UMMC from 2013 to 2015 and has been a trainer for the Master of Clinical Oncology programme at Universiti Malaya since 2006. She was inducted as a Member of College of Radiology, Academy of Medicine, Malaysia in 2009. She is an executive committee member of Malaysian Oncological Society. Her areas of special interest include genitourinary cancer, sarcoma, breast and gastrointestinal cancers. She is the principal investigator of numerous multi-centre clinical trials in genitourinary cancers including LATITUDE, KEYNOTE-052, IMvigor130, and the currently ongoing studies MAGNITUDE and KEYNOTE-992.
Prof. Dr. Ong Teng Aik
Prof Ong is currently the Vice President of the Malaysian Urological Association (MUA) and the Head of the Division of Urology, Faculty of Medicine, University of Malaya, Kuala Lumpur. Prof Ong is actively involved in a number of Asian multi-centre collaborative research activities, including the South East Asia Think Tank Group on Lower Urinary Tract Symptoms and the A-Cap Asia Pacifc Prostate Cancer Registry.Together with the clinical oncologists, Prof Ong set up the first Uro-Oncology Combined Clinic in the University of Malaya Medical Centre, Kuala Lumpur, in 2010. The clinic had since been the model of how urologists could work together with the oncologists to improve patient care.